Gary Schiller

Featured in: Favicon

nature.com Favicon

acpjournals.org Favicon

bloodjournal.org Favicon

onclive.com Favicon

targetedonc.com Favicon

doximity.com Favicon

opmed.doximity.com

Articles

Three-year analysis of adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3 | Leukemia

1 month ago | nature.com | Bijal Shah |Ryan D. Cassaday |Jae Park |Nicolas Boissel |Yi Lin |Gary Schiller | +5 more

AbstractBrexucabtagene autoleucel (brexu-cel) is an autologous anti-CD19 CAR T-cell therapy approved in the US to treat adults aged ≥18 years (≥26 years in the EU) with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Brexu-cel showed an overall complete remission (CR)/CR with incomplete hematologic recovery (CRi) rate of 73% (CR rate 60%) and median overall survival (OS) of 25.4 months in 78 patients with R/R B-ALL after 2 years in ZUMA-3.
Clinical Presentation and Diagnosis of BPDCN

Apr 15, 2024 | targetedonc.com | Gary Schiller

Case: Management of Elderly Transplant-Ineligible BPDCN PatientsClinical Presentation:A 74-year-old lady presents with fatigue, bruising like lesion on upper chest, and shortness of breath that had been present for around 6 months. Initial Clinical Workup and Diagnosis:Initially suspected to have acute myeloid leukemia (AML) based on preliminary workup at a community oncology clinic. Referred to academic cancer center for further evaluation after not responding well to initial AML treatment.
MDS: Canakinumab Phase 1b/2 Study

Feb 5, 2024 | targetedonc.com | Gary Schiller

2 Commerce Drive Cranbury, NJ 08512
Biomarker Analysis and Patient-Reported Outcomes from COMMANDS Study in MDS

Jan 29, 2024 | targetedonc.com | Gary Schiller

Biomarker Analysis and Patient-Reported Outcomes from COMMANDS Study in MDSAn expert on MDS reviews the biomarker analysis and patient-reported outcomes from the COMMANDS study as well as long-term outcomes from the MEDALIST study.
MDS: Patient-Reported Outcomes and Imetelstat Toxicity in IMerge Phase 3 Trial

Jan 29, 2024 | targetedonc.com | Gary Schiller

Dr Schiller reviews data updates from the IMerge phase 3 trial looking at patient-reported outcomes and cytopenias in patients with MDS following imetelstat treatment.
Durable Transfusion Independence in Lower-Risk MDS

Jan 29, 2024 | targetedonc.com | Gary Schiller

This is a video synopsis of a discussion featuring Gary J. Schiller, MD, chief of the Hematological Malignancy/Stem Cell Transplantation program at the David Geffen School of Medicine at UCLA Health Jonsson Comprehensive Cancer Center. In an abstract presented by Komrokji et al. from 4 US centers and 1 center in India, the impact of transfusion dependence on survival in lower risk MDS was analyzed. The endpoint of transfusion independence is used in many MDS trials but can be problematic.
Current Treatment Landscape for Patients with Lower-Risk MDS

Jan 15, 2024 | targetedonc.com | Gary Schiller

Different Approaches Available for Identifying and Managing Chronic GVHDIn the first article of a 2-part series, Lori Muffly, MD, MS, discusses with a panel of physicians what their approach is to identifying patients with severe chronic graft-versus-host-disease and how they treat them in conjunction with the transplant team.